Novartis to Work With Amgen on Alzheimer’s and Migraine Drugs

  • Swiss giant targets treatments for neurological conditions
  • Amgen to make upfront payment, milestones on Alzheimer's

Novartis AG said it formed a partnership with California biotechnology company Amgen Inc. to develop new drugs for Alzheimer’s disease and migraines, the latest step in the Swiss drugmaker’s plan to build a portfolio of treatments for neurological illnesses.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.